Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios A Dimopoulos, Ramón García‐Sánz, Hui‐Peng Lee, Marek Trněný, Marzia Varettoni, Stephen Opat, Shirley D’Sa, Roger G. Owen, Gavin Cull, Stephen P. Mulligan, Jarosław Czyż, Jorge J. Castillo, Marina Motta, Tanya Siddiqi, Mercedes Gironella, Miquel Granell, Dipti Talaulikar, Pier Luigi Zinzani, Elham Askari, Sebastian Grosicki, Albert Oriol, Simon Rule, Janusz Kłoczko, Alessandra Tedeschi, Christian Buske, Véronique Leblond, Judith Trotman, Wai‐Yee Chan, Jan Michel, Jingjing Schneider, Ziwen Tan, Aileen Cohen, Jane Huang, Constantine S. Tam (2020). Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. , 4(23), DOI: https://doi.org/10.1182/bloodadvances.2020003010.
